|
|
|
| Clinical problems awaiting solution |
| Clinical problems for which we found no evidence to act upon. If you know of any good evidence, please write us at webmaster@ebpcenter.com. |
 |
| Category |
Side effect
|
| Patients |
Schizophrenia |
| Exposure |
Antipsychotics |
| Comparison |
|
| Outcome |
Teratogenecity |
| EER |
|
| CER |
|
| NNT/NNH |
|
| Comments |
In a cohort study of 98 women exposed in the first trimester for the treatment of hyperemesis gravidarum, no malformations were found. Birth weight, duration of pregnancy, and fetal-neonatal mortality were not affected (J Clin Pharmacol 1969;9:224-7). However, in this study, only 1.2 mg/day of haloperidol was prerscribed for a few days to several weeks only.
A meta-analysis showed phenothiazines not to be teratogenic in humans (Drugs 2000;59:781-800). But most of these studies, again, were concerned with phenothiazines used as antiemetics, without mention of the dosage actually administered.
No similar data could be found for newer generation of antipsychotics.
It therefore appears that safety of antipsychotics, used with psychiatric populations, has not yet been established |
| Reference |
|
| Appraiser |
Dr Toshimi Yamada |
| Lastappraised |
8/27/2001 |
|
From RCT into NNT
